{"version":"1.0","type":"link","title":"Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma.","author_name":"Tiu C 외","author_url":"https://prs-insight.online/author/Tiu%20C","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/166756","thumbnail_width":1200,"thumbnail_height":630}